Related Experiment Videos
Acarbose treatment in obesity: a controlled study.
F Bayraktar1, F Hamulu, A G Ozgen
1Ege University Medical Faculty, Endocrinology Department, Bornova, Izmir, 35100 Turkey.
Eating and Weight Disorders : EWD
|March 10, 2001
Summary
Acarbose, an alpha-glucosidase inhibitor, did not provide additional benefits for weight loss in obese women when combined with a low-calorie diet. Diet alone was equally effective in reducing body weight and BMI.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Pharmacology
Background:
- Acarbose is an alpha-glucosidase inhibitor that impacts carbohydrate digestion.
- Obesity is a significant metabolic disorder with various treatment strategies.
- Understanding the role of pharmacological interventions alongside dietary changes is crucial.
Purpose of the Study:
- To evaluate the efficacy of acarbose as an adjunct therapy for obesity treatment.
- To compare the effects of a low-calorie diet with and without acarbose on anthropometric and metabolic parameters.
Main Methods:
- A randomized controlled trial involving 50 obese women over 12 weeks.
- Participants followed a 15 kcal/kg/day low-calorie diet.
- The study group received acarbose (150-300 mg/day), while the control group received a placebo.
Main Results:
- Both groups experienced significant reductions in body weight, BMI, and skinfold thickness.
- The acarbose group showed a significant decrease in basal insulin and triglyceride levels.
- The control group exhibited significant reductions in total cholesterol, LDL cholesterol, and triglyceride levels; triglyceride reduction was greater in the control group.
Conclusions:
- Acarbose therapy, when added to a low-calorie diet, does not offer superior benefits for weight reduction in obese women.
- Low-calorie diet therapy alone is as effective as combined therapy for managing obesity-related parameters.